Transforming growth factor α levels in pancreatic fluid

Courtney J. Doyle, Narasimhan P. Agaram, Michele Yip-Schneider, C. Schmidt

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: To determine if the level of transforming growth factor α (TGF-α) in the pancreatic fluid (PF) can diagnose intraductal papillary mucinous neoplasm (IPMN) versus other cystic lesions of the pancreas in patients. METHODS: Pancreatic fluid was prospectively obtained from patients during routine endoscopy and/or operation at Indiana University Hospital. Pancreatic fluid TGF-α levels were analyzed by enzyme-linked immunosorbent assay. Intraductal papillary mucinous neoplasm tissue was also analyzed by TGF-α immunohistochemistry. RESULTS: Sixty-nine fluid samples from 58 patients with the following pathologically confirmed pancreatic disorders were analyzed: IPMN (26 patients), serous cystadenoma (6), mucinous cystic neoplasm (9), pseudocysts (5), non-IPMN-associated pancreatic ductal adenocarcinoma (6), and sphincter of Oddi dysfunction (6). There was no significant difference between the mean PF-TGF-α levels in each category or between different dysplastic grades of IPMN. However, of all the diagnoses examined, only IPMN demonstrated PF-TGF-α levels greater than 95 pg/mL. In low-grade IPMN specimens, TGF-α immunohistochemistry correlated with enzyme-linked immunosorbent assay levels. CONCLUSIONS: The mean PF-TGF-α levels are not significantly different in IPMN lesions compared with those in other cystic pancreatic lesions, pancreatic ductal adenocarcinoma, or sphincter of Oddi dysfunction. However, PF-TGF-α levels more than 95 pg/mL may be useful in diagnosing IPMN. This assertion requires prospective validation.

Original languageEnglish
Pages (from-to)260-264
Number of pages5
JournalPancreas
Volume40
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Transforming Growth Factors
Neoplasms
Sphincter of Oddi Dysfunction
Pancreatic Neoplasms
Adenocarcinoma
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Serous Cystadenoma
Endoscopy
Pancreas

Keywords

  • IPMN
  • MCN
  • pancreatic adenocarcinoma
  • SCA
  • TGF-α

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Transforming growth factor α levels in pancreatic fluid. / Doyle, Courtney J.; Agaram, Narasimhan P.; Yip-Schneider, Michele; Schmidt, C.

In: Pancreas, Vol. 40, No. 2, 03.2011, p. 260-264.

Research output: Contribution to journalArticle

Doyle, Courtney J. ; Agaram, Narasimhan P. ; Yip-Schneider, Michele ; Schmidt, C. / Transforming growth factor α levels in pancreatic fluid. In: Pancreas. 2011 ; Vol. 40, No. 2. pp. 260-264.
@article{6eb05efbf33e4b4490742f0b073ba861,
title = "Transforming growth factor α levels in pancreatic fluid",
abstract = "OBJECTIVE: To determine if the level of transforming growth factor α (TGF-α) in the pancreatic fluid (PF) can diagnose intraductal papillary mucinous neoplasm (IPMN) versus other cystic lesions of the pancreas in patients. METHODS: Pancreatic fluid was prospectively obtained from patients during routine endoscopy and/or operation at Indiana University Hospital. Pancreatic fluid TGF-α levels were analyzed by enzyme-linked immunosorbent assay. Intraductal papillary mucinous neoplasm tissue was also analyzed by TGF-α immunohistochemistry. RESULTS: Sixty-nine fluid samples from 58 patients with the following pathologically confirmed pancreatic disorders were analyzed: IPMN (26 patients), serous cystadenoma (6), mucinous cystic neoplasm (9), pseudocysts (5), non-IPMN-associated pancreatic ductal adenocarcinoma (6), and sphincter of Oddi dysfunction (6). There was no significant difference between the mean PF-TGF-α levels in each category or between different dysplastic grades of IPMN. However, of all the diagnoses examined, only IPMN demonstrated PF-TGF-α levels greater than 95 pg/mL. In low-grade IPMN specimens, TGF-α immunohistochemistry correlated with enzyme-linked immunosorbent assay levels. CONCLUSIONS: The mean PF-TGF-α levels are not significantly different in IPMN lesions compared with those in other cystic pancreatic lesions, pancreatic ductal adenocarcinoma, or sphincter of Oddi dysfunction. However, PF-TGF-α levels more than 95 pg/mL may be useful in diagnosing IPMN. This assertion requires prospective validation.",
keywords = "IPMN, MCN, pancreatic adenocarcinoma, SCA, TGF-α",
author = "Doyle, {Courtney J.} and Agaram, {Narasimhan P.} and Michele Yip-Schneider and C. Schmidt",
year = "2011",
month = "3",
doi = "10.1097/MPA.0b013e3181f94d2a",
language = "English",
volume = "40",
pages = "260--264",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Transforming growth factor α levels in pancreatic fluid

AU - Doyle, Courtney J.

AU - Agaram, Narasimhan P.

AU - Yip-Schneider, Michele

AU - Schmidt, C.

PY - 2011/3

Y1 - 2011/3

N2 - OBJECTIVE: To determine if the level of transforming growth factor α (TGF-α) in the pancreatic fluid (PF) can diagnose intraductal papillary mucinous neoplasm (IPMN) versus other cystic lesions of the pancreas in patients. METHODS: Pancreatic fluid was prospectively obtained from patients during routine endoscopy and/or operation at Indiana University Hospital. Pancreatic fluid TGF-α levels were analyzed by enzyme-linked immunosorbent assay. Intraductal papillary mucinous neoplasm tissue was also analyzed by TGF-α immunohistochemistry. RESULTS: Sixty-nine fluid samples from 58 patients with the following pathologically confirmed pancreatic disorders were analyzed: IPMN (26 patients), serous cystadenoma (6), mucinous cystic neoplasm (9), pseudocysts (5), non-IPMN-associated pancreatic ductal adenocarcinoma (6), and sphincter of Oddi dysfunction (6). There was no significant difference between the mean PF-TGF-α levels in each category or between different dysplastic grades of IPMN. However, of all the diagnoses examined, only IPMN demonstrated PF-TGF-α levels greater than 95 pg/mL. In low-grade IPMN specimens, TGF-α immunohistochemistry correlated with enzyme-linked immunosorbent assay levels. CONCLUSIONS: The mean PF-TGF-α levels are not significantly different in IPMN lesions compared with those in other cystic pancreatic lesions, pancreatic ductal adenocarcinoma, or sphincter of Oddi dysfunction. However, PF-TGF-α levels more than 95 pg/mL may be useful in diagnosing IPMN. This assertion requires prospective validation.

AB - OBJECTIVE: To determine if the level of transforming growth factor α (TGF-α) in the pancreatic fluid (PF) can diagnose intraductal papillary mucinous neoplasm (IPMN) versus other cystic lesions of the pancreas in patients. METHODS: Pancreatic fluid was prospectively obtained from patients during routine endoscopy and/or operation at Indiana University Hospital. Pancreatic fluid TGF-α levels were analyzed by enzyme-linked immunosorbent assay. Intraductal papillary mucinous neoplasm tissue was also analyzed by TGF-α immunohistochemistry. RESULTS: Sixty-nine fluid samples from 58 patients with the following pathologically confirmed pancreatic disorders were analyzed: IPMN (26 patients), serous cystadenoma (6), mucinous cystic neoplasm (9), pseudocysts (5), non-IPMN-associated pancreatic ductal adenocarcinoma (6), and sphincter of Oddi dysfunction (6). There was no significant difference between the mean PF-TGF-α levels in each category or between different dysplastic grades of IPMN. However, of all the diagnoses examined, only IPMN demonstrated PF-TGF-α levels greater than 95 pg/mL. In low-grade IPMN specimens, TGF-α immunohistochemistry correlated with enzyme-linked immunosorbent assay levels. CONCLUSIONS: The mean PF-TGF-α levels are not significantly different in IPMN lesions compared with those in other cystic pancreatic lesions, pancreatic ductal adenocarcinoma, or sphincter of Oddi dysfunction. However, PF-TGF-α levels more than 95 pg/mL may be useful in diagnosing IPMN. This assertion requires prospective validation.

KW - IPMN

KW - MCN

KW - pancreatic adenocarcinoma

KW - SCA

KW - TGF-α

UR - http://www.scopus.com/inward/record.url?scp=79951723798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951723798&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181f94d2a

DO - 10.1097/MPA.0b013e3181f94d2a

M3 - Article

VL - 40

SP - 260

EP - 264

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -